Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiation Therapy in Limited-Stage Small Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538
Abstract
Purpose: We report mature outcomes of patients with limited-stage small cell lung cancer randomly assigned to the 61.2 Gy concomitant boost (CB) thoracic radiation therapy (TRT) arm of Cancer and Leukemia Group B (CALGB) 30610/Radiation Therapy Oncology Group (RTOG) 0538. The CB arm was discontinued after planned interim analysis; however, the study provides the largest prospective data set using 61.2 Gy CB TRT.
Methods and materials: Eligible patients had limited-stage small cell lung cancer with regional lymph node involvement and Eastern Cooperative Oncology Group performance status 0 to 2. TRT began with either the first or second (of 4 total) cycle of cisplatin-based chemotherapy. Three-dimensional conformal radiation therapy or intensity modulated radiation therapy planning was required. In the initial phase of the trial, patients were randomly assigned with a 1:1:1 allocation to 45 Gy twice daily, 70 Gy once daily, and 61.2 Gy CB TRT.
Results: Ninety-three patients were assigned to receive 61.2 Gy CB TRT. After a median follow-up of 115 months for surviving patients, median overall survival and progression-free survival were 32.3 months (95% CI, 20.4-44.8 months) and 15.4 months (95% CI, 10.0-24.0 months), respectively. Five-year overall survival was 28.5% (95% CI, 20.6-39.6). Rates of grade 3 and 4 nonhematologic adverse events were 40.9% and 25%, including 16% dysphagia and 7% severe pulmonary toxicity.
Conclusions: CB TRT outcomes appear similar to contemporaneous…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.